Company news

Immunovant, Inc. news in 2026

Immunovant, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026

October 21, 2026

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

September 23, 2026

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

July 23, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

May 20, 2026

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

May 11, 2026

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

April 1, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

February 6, 2026

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

January 23, 2026

Calls in 2026

Decks in 2026